

OrganiGram Holdings Inc.

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A")

For the three and six months ended February 28, 2017

ORGANIGRAM HOLDINGS INC.
MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE AND SIX-MONTH PERIOD ENDED FEBRUARY 28, 2017

1.1 Introduction

This **Management Discussion and Analysis (“MD&A”)** document, prepared on April 18, 2017, should be read in conjunction with the interim condensed consolidated financial statements of OrganiGram Holdings Inc. (the “Company” or “OHI”) for the three and six-month periods ended February 28, 2017 and February 29, 2016.

Financial data in this MD&A is based on the interim condensed consolidated financial statements of the Company for the three and six-month periods ended February 28, 2017 and February 29, 2016 and are expressed in Canadian dollars and prepared in accordance with International Financial Reporting Standards (“IFRS”).

The offices of OHI are at 35 English Drive, Moncton, New Brunswick, E1E 3X3 and further inquiries regarding the Company may be directed to its Chief Executive Officer, Greg Engel, at (506) 384-1571, or by fax at (506) 384-4266, or by email to info@organigram.ca.

1.2 Forward-Looking Statements

Certain information herein contains or incorporates comments that constitute forward-looking information within the meaning of applicable securities legislation. Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans”, or “continue”, or similar expressions suggesting future outcomes or events. They include, but are not limited to, statements with respect to expectations, projections or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities; and, statements regarding our future economic performance. These statements are not historical facts but instead represent management beliefs regarding future events, many of which, by their nature are inherently uncertain and beyond management control. We have based these forward-looking statements on our current expectations about future events.

Although the forward-looking statements contained in this MD&A are based on what we believe are reasonable assumptions, these assumptions are subject to a number of risks beyond the Company’s control and there can be no assurance that actual results will be consistent with these forward-looking statements. Factors that could cause actual results to differ materially from those set forth in the forward-looking statements and information include, but are not limited to: financial risks; dependence on senior management; sufficiency of insurance; industry competition; general economic conditions and global events; product development, facility and technological risks; changes to government laws, regulations or policy, including environmental or tax, or the enforcement thereof; agricultural risks; supply risks; product risks; and, other risks and factors described from time to time in the documents filed by the Company with securities regulators. For more information on the risk factors that could cause our actual results to differ from current expectations, see **“7.1 Risks and Uncertainties”**.

All forward-looking information is provided as of the date of this MD&A. The Company does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required by law. Additional information about these assumptions, risks and uncertainties is contained in our filings with securities regulators and are available at www.sedar.com. Certain filings are also available on our web site at www.organigram.ca.

1.3 Business Environment

In 2001, the Government of Canada introduced a regulatory regime, the *Medical Marijuana Access Regulations* (“MMAR”), governing access of patients to marijuana for medical purposes. Since this time, the number of patients prescribed medical marijuana has grown and continued growth is predicted. Meanwhile, the medical marijuana regulatory regime has continued to evolve until, in June 2013, Health Canada announced the current regulatory regime, the *Marihuana for Medical Purposes Regulations* (“MMPR”) to replace the MMAR. Pursuant to the MMPR, companies are eligible to apply as a Licensed Producer (a “license”) of medical marijuana. This license permits a company to lawfully cultivate, possess and sell medical marijuana in conformance with the MMPR. Due to the regulatory barrier to entry, the anticipated growth in demand in the consumption of medical marijuana and the potential return on investment, a license is highly coveted by many companies.

The MMPR came into effect on April 1, 2014 and the Company received its initial license to operate as a Licensed Producer of medical marijuana on April 14, 2014. The license was renewed on March 28, 2017.

On August 24, 2016, the *Access to Cannabis for Medical Purposes Regulations* (“ACMPR”) replaced the MMPR as the governing regulations in respect of the production, sale and distribution of medical cannabis and cannabis oil. The replacement regulations were implemented as a result of the ruling by the Federal Court of Canada in the case of *Allard et al v. Canada* in which the MMPR was found to be unconstitutional in violation of the plaintiffs’ rights under section 7 of the Charter of Rights and Freedoms due to the restrictions placed on a patient’s ability to reasonably access medical cannabis. The Federal Court of Canada therefore upheld the patients’ rights to grow their own medical marijuana.

The ACMPR effectively combines the regulations and requirements of the MMPR, the *Marihuana Medical Access Regulations* and the section 56 exemptions relating to cannabis oil under the *Controlled Drugs and Substances Act* into one set of regulations. In addition, the ACMPR sets out the process patients are required to follow to obtain authorization from Health Canada to grow cannabis and to acquire seeds or plants from Licensed Producers to grow their own cannabis. Under the ACMPR, patients have three options for obtaining cannabis:

- (a) they can continue to access quality-controlled cannabis by registering with Licensed Producers;
- (b) they can register with Health Canada to produce a limited amount of cannabis for their own medical purposes; or
- (c) they can designate someone else to produce it for them.

With respect to (b) and (c), starting materials, such as plants or seeds, must be obtained from Licensed Producers. It is possible that (b) and (c) could significantly reduce the addressable market for the Company’s products and could materially and adversely affect the business, financial condition and results of operations of the Company. That said, management of the Company believes that many patients may be deterred from opting to proceed with options (b) or (c) since such steps require applying for and obtaining registration from Health Canada to grow cannabis, as well as the up-front costs of obtaining equipment and materials to produce such cannabis.

On April 13, 2017, the Government of Canada introduced legislation to legalize, strictly regulate and restrict access to cannabis. The proposed Cannabis Act would create a strict legal framework for controlling the production, distribution, sale and possession of cannabis in Canada. Following Royal Assent, the proposed legislation would allow adults to legally possess and use cannabis. This would mean that possession of small amounts of cannabis would no longer be a criminal offence and would prevent profits from going into the pockets of criminal organizations and street gangs. The Bill would also, for the first time, make it a specific criminal offence to sell cannabis to a minor and create significant penalties for those who engage young Canadians in cannabis-related offences.

Subject to Parliamentary approval and Royal Assent, the Government of Canada intends to provide regulated and restricted access to cannabis no later than July 2018.

1.4 Risks and Uncertainties

The Company's business is subject to risks inherent in a high growth, government regulated enterprise, and the Company has identified certain risks pertinent to its business, as further described under "**7.1 Risk Management**". Management attempts to assess and mitigate these risks by retaining experienced professional staff and assuring that the Board of Directors and senior management are monitoring these risks on a continual basis.

2.1 Nature and History of the Company's Business

The Company is licensed as a Licensed Producer of medical marijuana, including dried cannabis and cannabis oil, under the ACMPR. Pursuant to its License, the Company is permitted to possess, produce, sell, provide, ship, deliver, transport and destroy medical marijuana, marijuana plants (including plants and seeds) and cannabis oil, in conformity with the ACMPR, and made its first shipment of medical marijuana to registered patients in September 2014. As at the date hereof, the Company has one of 28 licenses to produce and sell medical marijuana and one of 19 licenses to produce and sell cannabis oil under the ACMPR. The Company has the only license to produce and sell both medical marijuana and cannabis oil in Atlantic Canada. Moreover, management believes that the Company benefits from a number of competitive advantages which will allow it to be strategically positioned for future potential developments in the industry.

The Company has entered into agreements with several organizations committed to helping first responders and veterans deal with chronic ailments. Under the terms of the agreements, each of the organizations will refer patients to OrganiGram. The Company continues to pursue, as part of its business model, further strategic partnerships and opportunities with other suppliers and organizations and continues to actively evaluate such opportunities.

Since commencing operations at its main facility located in Moncton, New Brunswick, the Company has continued to expand the main facility to create additional production capability. The Company has also strategically acquired a building adjacent to the main facility as well as the adjoining 10-acre property, which includes a 136,000 square foot industrial building.

The Company's License currently allows the Company to, among other things, produce up to 1,500 kilograms of dried cannabis, 500 kilograms of cannabis oil, and to sell and distribute within Canada up to 1,200 kilograms of dried cannabis and 500 kilograms of cannabis oil per year (the "**License**"). The License has a current term that began on March 28, 2017 and ends on March 27, 2018. It is anticipated that Health Canada will extend or renew the License at the end of its current term. See "**7.1 Risk Management**".

Medical marijuana and cannabis oil patients order from the Company primarily through the Company's online store or through the phone. Medical marijuana and cannabis oil is and will continue to be delivered by secured courier or other methods permitted by the ACMPR. The Company's prices vary based on grow time, strain yield and market prices. The Company may from time to time offer volume discount or promotional pricing.

The Company is also authorized for wholesale shipping of medical marijuana plant cuttings and dried bud to other Licensed Producers. The Company has already completed sales through its wholesale strategy and based on current costs, management expects the wholesale shipment strategy to continue. This sales channel requires minimal selling, general and administrative costs over and above the cost to produce plant cuttings and dried bud.

2.2 Business Outlook

On December 7, 2016, the Company closed a bought deal, including the full exercise of the over-allotment option. A total of 11,339,000 common shares of the Company were sold at a price of \$3.55 per Share, for aggregate gross proceeds of \$40,253,450. The proceeds will allow the ongoing development of 35 English Drive and 320 Edinburgh Drive to add additional capacity and permit the increased production of medical marijuana, cannabis oil, and related products. The increase in capacity is also to prepare for legalization of recreational use of marijuana in Canada. The Government of Canada announced on April 13, 2017, legislation to legalize the recreational use of marijuana in Canada by July 1, 2018.

The expansion at its main facility is expected to be completed and operational in the spring of 2018. The expansion plan provides for a significant increase in the Company's cannabis production capabilities, and is designed to increase total production capacity to approximately 26,000 kilograms per year of flower.

On February 23, 2017, the Company closed an agreement to acquire additional land and premises at 91 English Drive. The property sits on approximately 2.6 acres of land with a 6,000 square foot industrial building. The Company will consolidate the acquired property with its existing ACMPR licensed facilities at 35 English Drive with the anticipation to construct a state of the art 15,000 square foot commercial scale oils and extracts manufacturing facility that is engineered and designed in collaboration with TGS International LLC ("TGS").

The Company's License was renewed March 28, 2017 and currently allows the Company to, among other things, produce up to 1,500 kilograms of dried cannabis, 500 kilograms of cannabis oil, and to sell and distribute within Canada up to 1,200 kilograms of dried cannabis and 500 kilograms of cannabis oil per year (the "License"). The License has a current term that ends on March 27, 2018. It is anticipated that Health Canada will extend or renew the License at the end of its current term. See "7.1 Risk Management".

The Company appointed Greg Engel as its new chief executive officer, effective March 13, 2017. Mr. Engel, a medical marijuana, pharmaceutical, and biotechnology industry veteran succeeds Denis Arsenault who is stepping up to the newly created executive chairman's position. Engel will also join the Board of Directors of Organigram. Engel has served in a number of senior-level and executive positions in related industries over the past 25 years in Canada, US and Internationally.

On April 10, 2017, the Company announced a letter of intent ("LOI") to acquire Trauma Healing Centers. THC specializes in medical cannabis assessment and prescribing and sees patients on a referral basis offering a multi-disciplinary approach to healing chronic conditions. The Company believes this arrangement allows both companies the resources to scale up and achieve future expansion plans.

On December 30, 2016, the Company announced it was voluntarily recalling certain lots of medical marijuana which was supplied between August and December 2016. Following discussions with Health Canada, this was deemed a Type III recall, which is defined as "a situation in which the use of, or exposure to, dried marijuana, fresh marijuana or cannabis oil, marijuana plants or seeds is not likely to cause any adverse health consequences." On January 9, 2017, the Company announced that it had expanded its product recall to include additional product lots manufactured in 2016. Certain product lots of the expanded recall were deemed a Type II recall, a situation in which the use of, or exposure to, a product may cause temporary adverse health consequences or where the probability of serious adverse health consequences is remote.

This has resulted in the Company instituting a series of new protocols and adopting the concept of "Canada's Safest Cannabis" as an internal mantra, rolling out several multi-departmental initiatives as a strategy to commit to full transparency and quality control. The first initiative is full Certification of Analysis being posted for clients' review through the Company's client portal.

The recall resulted in the Company issuing \$2,026,349 in sales returns for credits to uninsured customers. In addition, \$1,307,708 of indirect production was expensed for inventory destroyed in March 2017. As well, the recall resulted in a loss of \$1,670,172 in change in fair value of biological assets and net realizable value to inventory for inventory that was voluntarily recalled, in addition to the write-down of \$499,857 expensed in the three-month period ended November 30, 2017.

During the three months ended February 28, 2017, sales of oil products were 139,200 millilitres, an increase of 80% from the previous three months. The cash and short-term investment balance was at \$55,603,513 on February 28, 2017.

We believe these initiatives mentioned will position the Company for continued growth in sales and increase long-term shareholder value.

2.3 Selected Information

CAUTIONARY NOTE REGARDING NON-GAAP FINANCIAL MEASURES


The Company uses certain non-GAAP performance measures such as adjusted EBITDA (excluding fair value adjustment to inventory and biological assets), adjusted gross margin and adjusted gross profit within this MD&A or in documents incorporated by reference herein, which are not measures calculated in accordance with IFRS and have limitations as analytical tools. These performance measures have no meaning under IFRS and therefore amounts presented may not be comparable to similar data presented by other companies. The data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance such as net income or other data prepared in accordance with IFRS.

The following are quarterly financial highlights ended February 28, 2017.

Grams Sold – dried bud

The Company quantifies dried bud sold in the measurement of grams. Cannabis oil and accessories are measured separately.


Organigram Holdings Inc



ML Sold – Cannabis Oil

The Company quantifies cannabis oil sold in the measurement of milliliters and started selling the product in August 2016.


Organigram Holdings Inc



Net Sales

The net sales for the Company are defined as gross sales, less any customer discounts and returns. Primarily consisting of dried marijuana, it also includes revenue from cannabis oil and related accessories.

Organigram Holdings Inc



Adjusted Gross Margin % (excludes F.V. adjustment to bio-assets and inventory)

This is a non-GAAP measure and the Company calculates adjusted gross margin as net sales less cost of goods sold and indirect production, divided into net sales. The fair value adjustment to biological assets and inventory is excluded as management believes the exclusion is a better representation of performance. The fair value adjustment is a non-cash gain (loss) and is based on fair market value less cost to sell. The most directly comparable measure calculated in accordance with IFRS is gross margin.

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Gross Margin % (Excluding F.V. Adj.)	F2015	F2015	F2016	F2016	F2016	F2016	F2017	F2017
Gross Margin	651,826	720,168	640,834	1,082,648	1,581,961	2,008,801	762,891	(3,977,344)
Less: fair value adjustment to biological assets and inventory	637,164	328,665	78,817	297,716	687,651	937,509	(689,035)	(366,986)
Gross Margin excluding fair value adjustment to biological assets and inventory	14,662	391,503	562,017	784,932	894,310	1,071,292	1,451,927	(3,610,358)
Divided by: Net Sales	230,054	675,529	1,029,376	1,425,466	1,806,849	1,865,932	2,230,671	(581,169)
Gross Margin % (Excluding F.V. Adj.)	6%	58%	55%	55%	49%	57%	65%	-621%

Adjusted Net Profit

This is a non-GAAP measure and the Company calculates adjusted net profit as net profit before the fair value adjustment to biological assets and inventory. Management believes the exclusion is a better representation of performance. The fair value adjustment is a non-cash gain (loss) and is based on fair market value less cost to sell. The most directly comparable measure calculated in accordance with IFRS is net income (loss).

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Net Profit (Excluding F.V. Adj.)	F2015	F2015	F2016	F2016	F2016	F2016	F2017	F2017
Net income (loss)	119,695	56,926	(201,211)	55,267	367,720	624,887	(755,547)	(5,755,215)
Less: fair value adjustment to biological assets and net realizable value adjustment to inventory	637,164	328,665	78,817	297,716	687,651	937,509	(689,035)	(366,986)
Net Profit (Excluding F.V. Adj.)	(517,469)	(271,740)	(280,027)	(242,449)	(319,931)	(312,623)	(66,512)	(5,388,229)

Adjusted EBITDA

This is a non-GAAP measure and the Company calculates adjusted EBITDA as net profit before interest, income tax, depreciation and amortization, and the fair value adjustment to biological assets and inventory. Management believes the exclusion of the fair value adjustment is a better representation of performance. The fair value adjustment is a non-cash gain (loss) and is based on fair market value less cost to sell. The most directly comparable measure to adjusted EBITDA (excluding fair value adjustment to inventory and biological assets) calculated in accordance with IFRS is net income (loss).

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Adjusted EBITDA	F2015	F2015	F2016	F2016	F2016	F2016	F2017	F2017
Net income (loss)	119,695	56,926	(201,211)	55,267	367,720	624,887	(755,547)	(5,755,215)
Add:								
Interest	29,088	46,454	76,852	110,784	117,107	94,232	36,543	(132,539)
Income tax	-	-	-	-	-	-	-	-
Depreciation and amortization	147,460	115,018	141,103	195,864	203,726	244,883	302,808	805,944
Less: fair value adjustment to biological assets and net realizable value adjustment to inventory	637,164	328,665	78,817	297,716	687,651	937,509	(689,035)	(366,986)
Adjusted EBITDA	(340,920)	(110,267)	(62,072)	64,199	903	26,492	272,839	(4,714,824)

Cash Flow

This is a non-GAAP measure and the Company calculates cash flow as net profit before income tax, depreciation, share-based compensation, and the fair value adjustment to biological assets and inventory. Management believes the exclusions are a better representation of cash performance. The fair value adjustment is a non-cash gain (loss) and is based on fair market value less cost to sell. The most directly comparable measure calculated in accordance with IFRS is net income (loss).

	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Cash Flow	F2015	F2015	F2016	F2016	F2016	F2016	F2017	F2017
Net income (loss)	119,695	56,926	(201,211)	55,267	367,720	624,887	(755,547)	(5,755,215)
Add:								
Income tax	-	-	-	-	-	-	-	-
Depreciation and amortization	147,460	115,018	141,103	195,864	203,726	244,883	302,808	805,944
Share-based compensation	62,459	18,161	164,768	46,701	66,570	164,321	273,719	291,395
Less: fair value adjustment to biological assets and net realizable value adjustment to inventory	637,164	328,665	78,817	297,716	687,651	937,509	(689,035)	(366,986)
Cash Flow	(307,549)	(138,560)	25,844	116	(49,635)	96,581	510,015	(4,290,890)

3.1 Subsequent Events

(i) Issuance of stock options

On March 1, 2017, the Company has issued 20,000 employee options to purchase 20,000 common shares of the Company, to employees of OGI, at an exercise price of \$2.88 per share. Options vest over a two-year period. Vested options may be exercised until 2027, subject to forfeiture provisions requiring the options to expire ninety days after termination of the individual's employment.

On March 14, 2017, the Company has issued an aggregate of 1,500,000 incentive stock options to Greg Engel, a director of the Company and the Company's Chief Executive Officer, at an exercise price of \$2.36 per share.

In accordance with Mr. Engel's employment contract, (i) 266,666 of the Options shall vest on March 13, 2018; (ii) 266,667 of the Options shall vest on March 13, 2019; and (iii) 266,667 of the Options shall vest on March 13, 2020.

Additionally, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than \$4.76/share; and, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than \$7.14/share. In each instance, the common shares of the Company must trade at or greater than the price set forth above for a period of not less than 20 consecutive trading days.

(ii) Legal – Class Action Suit

On March 3, 2017, a Notice of Action was filed with the Supreme Court of Nova Scotia seeking certification to commence a class action lawsuit against the Company and OGI seeking damages in respect of any profits earned by the Company in respect of product which was sold to clients and subsequently voluntarily recalled.

The Company will be opposing certification and defending any action. While the legal analysis is ongoing, the Company does not believe, at this time, that there is a high probability of a significant damages award being awarded to the class, in the event that the class is certified to proceed. The Company has recognized in the three and six-month periods ended February 28, 2017, \$2,026,349 in sales returns to uninsured customers for credits arising from the product recall which represents a divestiture of the profits earned through a client credit program.

(iii) Letter of Intent to acquire Trauma Healing Centers

On April 10, 2017, the Company entered into a letter of intent (the “LOI”) to acquire all of the issued and outstanding shares of Trauma Healing Centers Incorporated (“THC”).

Under the terms of the LOI, the purchase consideration consists of the issuance of 719,425 common shares of the Company at a deemed value of \$2.78 per share.

THC specializes in medical cannabis assessment and prescribing. THC sees patients on a referral basis and offers a multi-disciplinary approach to healing chronic conditions.

4.1 Changes in Accounting Policies

New standards and interpretations adopted:

Amendments to IAS 41 – Agriculture and IAS 16 – Property, plant and equipment

This amendment provides guidance regarding the accounting for bearer plants by providing a definition of bearer plants and brings bearer plants within the scope of IAS 16 Property, plant and equipment from IAS 41 Agriculture. The amendment is effective for annual reporting periods beginning on or after January 1, 2016, and must be applied retrospectively. The Company has adopted these amendments in its financial statements for the year beginning on September 1, 2016. These amendments did not require any significant change to the Company’s accounting practices.

Disclosure Initiative (Amendments to IAS 1)

On December 18, 2014, the IASB issued Disclosure Initiative (Amendments to IAS 1) as part of its major initiative to improve presentation and disclosure in financial reports. The amendments to IAS 1 relate to (i) materiality; (ii) order of the notes; (iii) subtotals; (iv) accounting policies; and (v) disaggregation and are designed to further encourage companies to apply professional judgment in determining what information to disclose in their financial statements. For example, the amendments make clear that materiality applies to the whole of financial statements and that the inclusion of immaterial information can inhibit the usefulness of financial disclosures. Furthermore, the amendments clarify that companies should use professional judgment in determining where and in what order information is presented in the financial disclosures. The standard is effective for annual periods beginning on or after January 1, 2016. The Company has adopted these amendments in its financial statements for the year beginning on September 1, 2016. These amendments did not require any significant change to the Company’s accounting practices.

5.1 Pre -Tax Operating Earnings

The following are the statements of income for the quarter ended February 28, 2017 and 2016:

	3-Months Ended February 28		6-Months Ended February 28	
	2017	2016	2017	2016
Revenue				
Sales	\$ 1,445,180	\$ 1,425,466	\$ 3,675,851	\$ 2,454,842
Less: sales returns	(2,026,349)	-	(2,026,349)	-
Net sales	(581,169)	1,425,466	1,649,502	2,454,842
Cost of sales	941,939	565,252	1,629,200	998,373
Indirect production	2,087,250	75,281	2,178,734	109,520
	(3,610,358)	784,933	(2,158,432)	1,346,949
Fair value adjustment to biological assets and net realizable value adjustment to inventory	(366,986)	297,715	(1,056,021)	376,533
Gross margin	<u>(3,977,344)</u>	<u>1,082,648</u>	<u>(3,214,453)</u>	<u>1,723,482</u>
Expenses				
Sales and marketing	704,571	412,015	1,372,491	737,403
General and administrative	914,444	449,660	1,454,699	724,693
Share-based compensation	291,395	46,699	565,114	211,466
Total expenses	<u>1,910,410</u>	<u>908,374</u>	<u>3,392,304</u>	<u>1,673,562</u>
(Loss) income from operations	<u>(5,887,754)</u>	<u>174,274</u>	<u>(6,606,757)</u>	<u>49,920</u>
Financing costs	62,980	119,007	163,938	195,864
Investment income	(195,519)	-	(259,933)	-
Net (loss) income and comprehensive (loss) income	<u>\$ (5,755,215)</u>	<u>\$ 55,267</u>	<u>\$ (6,510,762)</u>	<u>\$ (145,944)</u>
Weighted-average number of shares, basic and diluted	<u>97,082,387</u>	<u>56,287,311</u>	<u>91,965,738</u>	<u>54,707,208</u>
Net (loss) income per common share, basic and diluted	<u>\$ (0.059)</u>	<u>\$ 0.001</u>	<u>\$ (0.071)</u>	<u>\$ (0.003)</u>

5.2 Results of operations for the quarter ending February 28, 2017

Summary of Quarterly Results

	Q3 F2015	Q4 F2015	Q1 F2016	Q2 F2016	Q3 F2016	Q4 F2016	Q1 F2017	Q2 F2017
Net Sales	230,054	675,529	1,029,376	1,425,466	1,806,849	1,865,932	2,230,671	(581,169)
Net income (loss)	119,695	56,926	(201,211)	55,267	367,720	624,887	(755,547)	(5,755,215)
Net income (loss) per common share, basic and diluted	0.002	(0.024)	(0.004)	0.001	0.007	0.009	(0.009)	(0.059)

Revenue

Organigram sales include wholesale, cannabis oil, and accessories revenue. For the quarter ended February 28, 2017, the Company posted net sales of \$(581,169) from 141,640 grams of dried bud and 139,200 ml of oil sold versus \$1,425,466 for the quarter ended February 29, 2016 on sales of 169,215 grams of dried bud and nil ml of oil. Included in net sales for the quarter ended February 28, 2017 were sales of \$1,445,180 less \$2,026,349 in sales returns due to the voluntary recall. Due to the voluntary recall, product availability was limited during the quarter.

Organigram posted revenue for the six months ended February 28, 2017 of \$1,649,502 on 401,931 grams of dried bud and 216,400 ml of oil sold versus \$2,454,842 on 312,005 grams of dried bud and nil ml of oil sold for the six months ended February 29, 2016. Included in net sales for the six months ended February 28, 2017 were sales returns of \$2,026,349 due to the voluntary recall. Due to the voluntary recall, product availability was limited during the second quarter of period ending February 28, 2017.

Gross Margin

The gross margin for the quarter ended February 28, 2017 and 2016 was \$(3,977,344) and \$1,082,648 respectively. The decrease in gross margin compared to prior year was the result of several factors related to the voluntary recall during the second quarter. Sales returns of \$2,026,349 were posted during the quarter compared to nil for the quarter ending February 29, 2016.

The cost of sales currently consists of three main categories:

- 1) Costs of goods sold include the direct costs of materials and labour related to the medical marijuana sold. This includes growing, cultivation and harvesting costs, quality assurance and quality control, as well as packaging and labelling. It also includes the costs of sales related to other products such as vaporizers and cookbooks.
- 2) Depreciation of manufacturing related items such as building and equipment, utilized in the production of medical marijuana.
- 3) Change in the fair value of biological assets and inventory related to IFRS standard IAS41.

The voluntary recall resulted in 59% of dried bud grams sold being outsourced product to help meet customer demand during the recent three-month period. This contributed to a higher cost per gram sold.

Indirect production for the three-month period ended February 28, 2017 was \$2,087,250 versus \$75,281 for the three months ended February 29, 2016. Included in the recent quarter was \$1,307,708 posted for voluntarily recalled product and \$348,527 for obsolete product destroyed in March 2017.

As a result of the voluntary recall, during the recent quarter, a loss was incurred of \$1,670,172 in change in fair value of biological assets and net realizable value adjustment to inventory.

The gross margin for the six-month period ended February 28, 2017 and 2016 was \$(3,214,453) and \$1,723,482 respectively. Included in the gross margin for the recent six-month period are adjustments related to the voluntary recall; sales returns of \$2,026,349, indirect production of \$1,307,708, and a loss of \$2,170,029 in change in fair value of biological assets and net realizable value adjustment to inventory.

Sales and marketing

In the quarter ending February 28, 2017, the Company incurred sales and marketing expenses of \$704,571 versus \$412,015 in the quarter ended February 29, 2016. These costs are related to commissions on sales, medical liaison staff, the Company's client services operations, delivery costs, as well as educational materials.

In the six-month period ending February 28, 2017, the Company incurred sales and marketing expenses of \$1,372,491 versus \$737,403 in the six months ended February 29, 2016. These costs are related to commissions on sales, medical liaison staff, the Company's client services operations, delivery costs, as well as educational materials.

The increase from the comparable periods is due to planning for the recreational market.

General and Administrative

In the quarter ended February 28, 2017, the Company incurred expenses of \$914,444 versus \$449,660 in the comparable 2016 prior period.

In the six-month period ending February 28, 2017, the Company incurred expenses of \$1,454,699 versus \$724,693 in the six months ended February 29, 2016.

The increase from the comparable periods is related to an increase in internal resources, accounting, legal, and shareholder related fees as the Company continues planning for the recreational market.

Share-based compensation

The company recognized \$291,395 in share-based compensation for the quarter ended February 28, 2017 compared to \$46,669 in the quarter ended February 29, 2016. Options granted in the recent period were 245,000 compared to 180,000 in the quarter ended February 29, 2016.

The company recognized \$565,114 in share-based compensation for the six-month period ended February 28, 2017 compared to \$211,466 in the six-month period ended February 29, 2016. Options granted in the recent six-month period were 2,238,100 compared to 1,109,165 in the six month period ended February 29, 2016.

Share-based compensation was valued using the Black-Scholes valuation model and represents a non-cash expense.

Financing costs and investment income

For the quarter ending February 28, 2017, the Company incurred \$62,980 in financing costs less \$195,519 in investment income versus \$119,007 in financing costs in quarter ended February 29, 2016.

For the six-month period ending February 28, 2017, the Company incurred \$163,938 in financing costs less \$259,933 in investment income versus \$195,864 in financing costs in the six month period ended February 29, 2016.

These costs are related to long-term debt of \$3,283,186 at February 28, 2017. The investment income is related to the short-term investments of \$54,275,000 at February 28, 2017.

During the first quarter ended November 30, 2016, the \$1,000,000 non-brokered private placement loan maturing September 1, 2017, bearing interest at an interest rate of 9%, was repaid. Additionally, the \$2,900,000 private placement convertible debentures maturing December 31, 2018, bearing interest at an interest rate of 6.75%, was converted into common shares.

The long-term debt received is as follows:

	February 28, 2017	August 31, 2016
Farm Credit Canada credit facility - with a 10 year amortization and a 5 year term variable rate plus 1.75% (currently 5.45%)	2,067,594	2,175,496
Non-brokered private placement maturing September 1, 2017, bearing interest at an interest rate of 9%, repaid	-	1,000,000
Farm Credit Canada - real property loan maturing December 1, 2020 with a 10 year amortization and 5 year term variable rate plus 2.15% (currently 5.936%)	1,378,850	1,424,318
Private placement convertible debentures maturing December 31, 2018 and bearing interest at an interest rate of 6.75% (Note 10)	-	2,900,000
Business Development Program - loan maturing September 1, 2024 with a 7 year amortization, bearing interest at an interest rate of 0%	204,398	-
<u>Deferred financing</u>	<u>(7,083)</u>	<u>(8,334)</u>
	3,643,759	7,491,480
<u>Less: current portion</u>	<u>(360,573)</u>	<u>(330,649)</u>
<u>Long-term portion</u>	<u>\$ 3,283,186</u>	<u>\$ 7,160,831</u>

The investment income earned is from the following:

<u>Description</u>	<u>Interest %</u>	<u>February 28, 2017</u>	<u>August 31, 2016</u>
Maturing November 30, 2016	0.80%	\$ -	\$ 300,000
Maturing June 9, 2017, redeemed	0.97%	-	500,000
Maturing June 22, 2017	1.01%	5,275,000	8,600,000
Maturing July 15, 2017, redeemed	0.95%	-	375,000
Maturing August 26, 2017	1.11%	6,500,000	6,500,000
Maturing August 26, 2017	1.11%	6,500,000	6,500,000
Maturing October 28, 2017	1.11%	1,000,000	-
Maturing December 22, 2017	1.19%	5,000,000	-
Maturing December 22, 2017	1.19%	5,000,000	-
Maturing December 27, 2017	1.20%	5,000,000	-
Maturing December 28, 2017	1.46%	<u>20,000,000</u>	<u>-</u>
		<u>\$ 54,275,000</u>	<u>\$ 22,775,000</u>

All short term investments are guaranteed investment certificates which are redeemable prior to maturity.

Net Loss

The net loss for the quarter ended February 28, 2017 was \$5,755,215 or \$(0.059) per share, compared to the quarter ending February 29, 2016 of a net income of \$55,267 or \$0.001 per share. Included in the net loss for the recent quarter are adjustments related to the voluntary recall; sales returns of \$2,026,349, indirect production of \$1,307,708, and a loss of \$1,670,172 in change in fair value of biological assets and net realizable value adjustment to inventory.

The net loss for the six-month period ending February 28, 2017 was \$6,510,762 or \$(0.071) per share, compared to the six-month period ending February 29, 2016 of a net loss of \$145,944 or \$(0.003) per share.

5.3 Related Party Transactions

Transactions and balances with related entities

A debenture to Denaco Group Ltd, a company controlled by the previous Chief Executive Officer, issued in July 2015 for \$500,000 through a non-brokered private placement repayable on September 1, 2017, carrying a 9% interest rate, was re-paid in the quarter ended November 30, 2016.

Certain directors, management, and other related parties controlled by directors of the company were issued convertible debentures as part of the November 27, 2015 private placement. The convertible debentures carried a 6.75% interest rate and were to expire on December 31, 2018. During the quarter ended November 30, 2016, these debentures were converted into 110,713 common shares.

Management and Board compensation

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the entity, directly or indirectly. The key management personnel of the Company are the members of the Company's executive management team and Board of Directors. For the three and six-month period ended February 28, 2017, the Company's expenses included \$198,675 (2016 - \$134,236) and \$365,773 (2016 - \$238,111) respectively for salary and/or consulting fees paid to key management personnel. In addition, nil options (2016 - 40,000) and 835,600 (2016 - 160,000) options were issued for the three and six month period respectively to key management personnel during the period at an average exercise price of \$nil (2016 - \$0.86) and \$1.42 (2016 - \$0.44) respectively.

6.1 Liquidity and Capital Resources

The following highlights the Company's cash flows during the six month period ended February 28, 2017 and 2016.

	February 28, 2017	February 29, 2016
<u>Net Cash Provided By (Used)</u>		
Operating Activities	\$ (2,536,164)	\$ (1,684,973)
Financing Activities	39,690,990	5,889,719
Investing Activities	<u>(45,683,950)</u>	<u>(4,688,965)</u>
Cash Provided (Used)	(8,529,124)	(484,219)
Cash Position		
Beginning of period	<u>9,857,637</u>	<u>\$ 1,473,694</u>
End of period	<u>\$ 1,328,513</u>	<u>\$ 989,475</u>

On February 28, 2017, the Company had a cash balance of \$1,328,513 compared to \$989,475 for the comparable period.

The cash used by operating activities was \$2,536,164 primarily driven by a net loss of \$6,510,762 offset by non-cash items for depreciation and loss on disposals of \$1,108,752, share-based compensation of \$565,114, and an increase in working capital balances of \$2,496,183. For the six months ended February 29, 2016, cash used by operating activities was \$1,684,973 primarily driven by a net loss of \$145,944 and a decrease in working capital balances of \$1,938,303, offset by non-cash items for depreciation of \$336,969 and share-based compensation of \$211,466.

The cash provided by financing activities was \$39,690,990 driven by a bought deal on December 7, 2016 for \$40,253,450 in shares issued and stock options and warrants exercised of \$3,160,817 offset by issue costs of \$2,611,617. For the six months ended February 29, 2016, cash provided by financing activities was \$5,889,719 primarily driven by a private placement financing of \$3,429,999 along with a \$2,900,000 convertible debenture loan.

The cash used by investing activities was \$45,683,950 primarily driven by acquisition of property, plant and equipment for \$14,698,040 and investing in short-term interest-bearing certificates for \$31,500,000. Property, plant and equipment included the acquisition of an adjacent property for expanding operations located at 320 Edinburgh drive in Moncton, New Brunswick for a purchase price of \$7,925,049, including closing costs. Another property located at 91 English drive in Moncton, New Brunswick was purchased for \$609,545, including closing costs. For the six months ended February 29, 2016, cash used by investing activities was \$4,688,965 by investing in short-term interest-bearing certificates for \$4,000,000 and property, plant and equipment for \$688,965.

6.2 Share Data

(i) Outstanding shares, warrants and options

The following table sets out the number of shares, warrants and options outstanding as at February 28, 2017 and April 18, 2017:

Fully Diluted Shares	February 28	April 18
Common shares issued and outstanding	101,088,255	101,678,246
Investor warrants	6,044,391	5,505,400
Agent warrants	-	-
Finders' warrants	-	-
Compensation options	4,768,849	6,297,849
Total fully diluted shares	<u>111,901,495</u>	<u>113,481,495</u>

(ii) Share-based compensation

Under the Company's stock option plan, options may be granted for up to 10% of the issued and outstanding common shares, as approved by the Company's Board of Directors. The exercise price of any option may not be less than the Company's closing market price on the day prior to the grant of the options less the applicable discount permitted by the TSX-V.

The maximum exercise period after the grant of an option is 10 years. When an employee's service ends, the expiry date of his/her options is accelerated to 90 days thereafter, or less, depending on the terms of the related option agreement.

The Company also issues stock options to third parties in exchange for services.

The change in the options outstanding during the period is as follows:

	Number	Average Exercise Price
Balance - September 1, 2016	2,742,862	\$0.67
Granted	1,993,100	\$1.49
Exercised	(120,030)	\$0.79
Cancelled / Forfeited	(6,000)	\$0.30
Balance - November 30, 2016	<u>4,609,932</u>	<u>\$1.02</u>
Granted	245,000	\$3.50
Exercised	(76,083)	\$0.98
Cancelled / Forfeited	(10,000)	\$2.54
Balance - February 28, 2017	<u>4,768,849</u>	<u>\$1.14</u>

Options outstanding have exercise prices that range from \$0.30 to \$3.55 with a weighted average remaining life of 8 years. Total share-based compensation expense for the three month period ended February 28, 2017 was \$291,395 (2016 – \$46,699) of which, \$285,923 related to the Company's stock option plan. For the six month period ending February 28, 2017, share-based compensation was \$565,114 (2016 - \$211,466) of which, \$435,317 related to the Company's stock option plan. These options are measured at fair value at the date of grant and are expensed over the option's vesting period. In determining the amount of share-based compensation, the Company used the Black-Scholes option pricing model to establish the fair value of options granted by applying the following assumptions:

Risk free interest rate	0.55% - 2.00%
Expected life of options	0.5 -8 years
Expected annualized volatility	53% -128%
Expected dividend yield	-

Volatility was estimated by using the historical volatility of other companies that the Company considers comparable that have trading and volatility history. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate is based on Canada government bonds with a remaining term equal to the expected life of the options.

6.3 Balance Sheet

The following is the financial position of the Company as at February 28, 2017 and August 31, 2016:

	February 28, 2017	August 31, 2016
Assets		
Current Assets		
Cash	\$ 1,328,513	\$ 9,857,637
Short term investments	54,275,000	22,775,000
Accounts receivable	2,470,821	1,561,893
Biological assets	2,928,704	2,366,863
Inventories	2,660,278	3,940,820
Prepaid expenses	<u>473,580</u>	<u>149,740</u>
	64,136,896	40,651,953
Property, plant and equipment	26,550,140	13,215,012
Deferred charges	<u>531,066</u>	<u>-</u>
	<u>\$ 91,218,102</u>	<u>\$ 53,866,965</u>
Liabilities		
Current Liabilities		
Accounts payable and accrued liabilities	\$ 4,856,729	\$ 2,115,193
Current portion of long term debt	<u>360,573</u>	<u>330,649</u>
	5,217,302	2,445,842
Long-term Debt		
Long-term debt	<u>3,283,186</u>	<u>7,160,831</u>
	<u>8,500,488</u>	<u>9,606,673</u>
Shareholders' Equity		
Share capital	95,737,403	50,958,174
Reserve for options and warrants	2,355,982	2,167,127
Accumulated deficit	<u>(15,375,770)</u>	<u>(8,865,009)</u>
	<u>82,717,614</u>	<u>44,260,292</u>
	<u>\$ 91,218,102</u>	<u>\$ 53,866,965</u>

As at the date hereof, the Company has no off-balance sheet arrangements.

6.4 Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants. The Company does not record any financial instruments at fair value. The Company's financial instruments include cash, short-term investments, accounts receivable, accounts payable and accrued liabilities and long-term debt. The carrying values of these financial instruments approximate fair value.

Fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- J Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date.
- J Level 2 inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- J Level 3 inputs are unobservable inputs for the asset or liability.

The fair value of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, and long-term debt are classified as a level 2 measurements. During the year, there were no transfers of amounts between level 1, 2 and 3.

7.1 Financial Risk Factors

The Company is exposed to various risks through its financial instruments, as follows:

- (i) **Credit risk** arises from deposits with banks, short-term investments and outstanding receivables. For trade receivables, the Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance. For other receivables out of the normal course of business, management may obtain guarantees and general security agreements. The maximum exposure to credit risk approximates the \$58,074,334 of cash, short term investments and accounts receivable on the balance sheet.

As of February 28, 2017 and August 31, 2016, the Company's aging of trade receivables (net of a provision for doubtful accounts) was approximately as follows:

	February 28, 2017	August 31, 2016
0-60 days	\$ 649,233	\$ 889,421
61-120 days	<u>470,871</u>	<u>77,672</u>
Total	<u>\$ 1,120,104</u>	<u>\$ 967,093</u>

Included in other accounts receivable is a secured promissory note receivable of \$100,000 bearing interest at 3% and payable on demand. Also included in other accounts receivable is a \$200,000 promissory note bearing interest at 5% and maturing on August 29, 2017.

- (ii) **Liquidity risk** - The Company's liquidity risk is the risk the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements. At February 28, 2017, the Company had \$1,328,513 (August 31, 2016 – \$9,857,637) of cash and cash equivalents and working capital of \$58,919,594 (August 31, 2016- \$38,206,111).

The Company is obligated to the following contractual maturities relating to their undiscounted cash flows:

	Carrying Amount	Contractual Cash Flows	Fiscal 2017	Fiscal 2018-2019	Fiscal 2020-2021
Accounts payable and accrued liabilities	\$ 4,856,729	\$ 4,856,729	\$ 4,856,729	\$ -	\$ -
Long-term debt	3,643,759	3,643,759	169,098	800,505	880,788
Interest	-	-	92,842	326,141	249,957
	<u>\$ 8,500,488</u>	<u>\$ 8,500,488</u>	<u>\$ 5,118,669</u>	<u>\$ 1,126,646</u>	<u>\$ 1,130,745</u>

(iii) **Market risk** is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of:

Interest risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk at February 28, 2017 pursuant to the variable rate loans described in the long-term debt schedule. A 1% change in prime interest rates will increase or decrease the Company's interest expense by \$34,464 per year.

(iv) **Concentration risk**

The Company's accounts receivable is primarily due from the Federal Government, legal trusts, and patients covered under group insurance, and, thus, the Company believes that the accounts receivable balance is collectible.

(v) **Dependence on Senior Management**

The success of the Company and its strategic focus is dependent to a significant degree upon the contributions of senior management. The loss of any of these individuals, or an inability to attract, retain and motivate sufficient numbers of qualified senior management personnel could adversely affect its business. This risk is partially mitigated by the fact that the senior management team are significant shareholders in the Company. As well, implementation of employee compensation packages, composed of monetary short-term compensation and long term stock based compensation, has been designed for the retention of key employees.

(vi) **Sufficiency of Insurance**

The Company maintains various types of insurance which may include financial institution bonds; errors and omissions insurance; directors', trustees' and officers' insurance; property coverage; and, general commercial insurance. There is no assurance that claims will not exceed the limits of available coverage; that any insurer will remain solvent or willing to continue providing insurance coverage with sufficient limits or at a reasonable cost; or, that any insurer will not dispute coverage of certain claims due to ambiguities in the policies. A judgment against any member of the Company in excess of available coverage could have a material adverse effect on the Company in terms of damages awarded and the impact on the reputation of the Company.

(vii) **Competition**

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and manufacturing and marketing experience than the Company.

Because of the early stage of the industry in which OHI operates, the Company expects to face additional competition from new entrants. If the number of users of medical marijuana in Canada increases, the demand for products will increase and OHI expects that competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products and pricing strategies. To remain competitive, OHI will require a continued high level of investment in marketing, sales and client support. The Company may not have sufficient resources to maintain marketing, sales and client support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations of the Company.

(viii) General Business Risk and Liability

Given the nature of Company's business, it may from time to time be subject to claims or complaints from investors or others in the normal course of business. The legal risks facing OHI, its directors, officers, employees or agents in this respect include potential liability for violations of securities laws, breach of fiduciary duty and misuse of investors' funds. Some violations of securities laws and breach of fiduciary duty could result in civil liability, fines, sanctions, or the suspension or revocation of the Company's right to carry on its existing business. The Company may incur significant costs in connection with such potential liabilities.

(ix) Regulation of the Marijuana Industry

OHI is heavily regulated in all jurisdictions where it carries on business. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over the activities of the Company, including the power to limit or restrict business activities as well as impose additional disclosure requirements on the Company's products and services.

Possible sanctions include the revocation or imposition of conditions on licenses to operate the Company's business; the suspension or expulsion from a particular market or jurisdiction or of its key personnel; and, the imposition of fines and censures. To the extent that existing or future regulations affect the sale or offering of the Company's product or services in any way, the Company's revenues may be adversely affected.

(x) Regulatory Risks

The business and activities of the Company are heavily regulated in all jurisdictions where it carries on business. The Company's operations are subject to various laws, regulations and guidelines by governmental authorities, particularly Health Canada, relating to the manufacture, marketing, management, transportation, storage, sale, pricing and disposal of medical marijuana and cannabis oil, and also including laws and regulations relating to health and safety, insurance coverage, the conduct of operations and the protection of the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over the activities of the Company, including the power to limit or restrict business activities as well as impose additional disclosure requirements on the Company's products and services.

Achievement of the Company's business objectives are contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the production and sale of its products. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the business, results of operations and financial condition of the Company.

Failure to comply with the laws and regulations applicable to its operations may lead to possible sanctions including the revocation or imposition of additional conditions on licenses to operate the Company's business; the suspension or expulsion from a particular market or jurisdiction or of its key personnel; and, the imposition of fines and censures. To the extent that there are changes to the existing laws and regulations or the enactment of future laws and regulations that affect the sale or offering of the Company's products or services in any way, the Company's revenues may be adversely affected.

While the Company currently anticipates the legalization of recreational marijuana use in Canada in the future, there can be no assurances that recreational marijuana use in Canada will in fact be legalized in the near term, or at all. The Company has invested a considerable amount of funds into the expansion of its production facilities, including the 35 English Drive, 91 English Drive, and the 320 Edinburgh Drive Expansion, in anticipation of the legalization of recreational marijuana use in Canada and any significant delay in legalization or a decision by the government of Canada and other relevant regulatory authorities to not proceed with legalization could have a material adverse effect on the business, results of operations and financial condition of the Company.

(xi) Change in Laws, Regulations and Guidelines

The Company's operations are subject to a variety of laws, regulations and guidelines relating to the marketing, acquisition, manufacture, management, transportation, storage, sale and disposal of medical marijuana but also including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment. While to the knowledge of the Company's management, it is currently in compliance with all such laws, changes to such laws, regulations and guidelines due to matters beyond the control of OHI may cause adverse effects to the Company's operations.

(xii) Reliance on License Renewal

OGI's ability to grow, store and sell medical marijuana in Canada is dependent on the license from Health Canada. Failure to comply with the requirements of the license or any failure to maintain this license would have a material adverse impact on the business, financial condition and operating results of the Company. The license was renewed March 28, 2017 and expires March 27, 2018. Although management believes it will meet the requirements of the ACMPR annually for extension of the license, there can be no guarantee that Health Canada will extend or renew the license or, if it is extended or renewed, that it will be extended or renewed on the same or similar terms. Should Health Canada not extend or renew the license, or should it renew the license on different terms or not allow for anticipated capacity increases, the business, financial condition and results of the operations of the Company will be materially adversely affected.

(xiii) Reliance on a Single Facility

To date, OGI's activities and resources have been primarily focused on its main production facility at 35 English Drive in Moncton, New Brunswick and OGI will continue to rely on this facility for the foreseeable future. Adverse changes or developments affecting the facility could have a material and adverse effect on the Company's business, financial condition and prospects.

(xiv) Factors which may Prevent Realization of Growth Targets

The Company's growth strategy contemplates outfitting the Moncton facility with additional production resources. There is a risk that these additional resources will not be achieved on time, on budget, or at all, as they can be adversely affected by a variety of factors, including some that are discussed elsewhere in these risk factors and the following:

- delays in obtaining, or conditions imposed by, regulatory approvals;
- failure to obtain anticipated license capacity increases;
plant design errors, non-performance by third party contractors, increases in materials or labour costs; or, construction performance falling below expected levels of output or efficiency
- environmental pollution;
- contractor or operator errors; or, breakdowns, aging or failure of equipment or processes;
- labour disputes, disruptions or declines in productivity; or, inability to attract sufficient numbers of qualified workers;
- disruption in the supply of energy and utilities; and
- major incidents and/or catastrophic events such as fires, explosions, earthquakes or storms.

As a result, there is a risk that the Company may not have product, or sufficient product, available for shipment, to meet the expectations of its potential customers or in its business plan.

(xv) Risks Inherent in an Agricultural Business

The Company's business involves the growing of medical marijuana, an agricultural product. As such, the business is subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks that may create crop failures and supply interruptions for the Company's customers. Although OGI grows its products indoors under climate controlled conditions and carefully monitors the growing conditions with trained personnel, there can be no assurance that natural elements will not have a material adverse effect on the production of its products.

(xvi) Vulnerability to Rising Energy Costs

OGI's medical marijuana growing operations consume considerable energy, making the Company vulnerable to rising energy costs. Rising or volatile energy costs may adversely impact the business of OGI and its ability to operate profitably.

(xvii) Publicity or Consumer Perception

The Company believes the medical marijuana industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the medical marijuana produced. Consumer perception of OGI's products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medical marijuana products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the medical marijuana market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for OGI's products and the business, results of operations, financial condition and the Company's cash flows. OGI's dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for OGI's products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of medical marijuana in general, or OGI's products specifically, or associating the consumption of medical marijuana with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products appropriately or as directed.

(xix) Product Liability

As a manufacturer and distributor of products designed to be ingested by humans, OGI faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the manufacture and sale of OGI's products involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of OGI's products alone or in combination with other medications or substances could occur. OGI may be subject to various product liability claims, including, among others, that OGI's products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against OGI could result in increased costs, could adversely affect OGI's reputation with its clients and consumers generally, and could have a material adverse effect on our results of operations and financial condition of the Company.

There can be no assurances that OGI will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of OGI's potential products. As of the current date, the Company has a small amount of insurance coverage for product liabilities.

(xx) Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of OGI's products are recalled due to an alleged product defect or for any other reason, OGI could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. OGI may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although OGI has detailed procedures in place for testing finished products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if one of OGI's significant brands were subject to recall, the image of that brand and OGI could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for OGI's products and could have a material adverse effect on the results of operations and financial condition of OGI.

Additionally, product recalls may lead to increased scrutiny of OGI's operations by Health Canada or other regulatory agencies, requiring further management attention and potential legal fees and other expenses.

(xxii) Reliance on Key Inputs

OGI's business is dependent on a number of key inputs and their related costs including raw materials and supplies related to its growing operations, as well as electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of OGI. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition and operating results of the Company.

(xxiii) Difficulties with Forecasts

OGI must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the medical marijuana industry in Canada. A failure in the demand for its products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.

(xxiv) Exchange Restrictions on Business

The TSX-V's listing conditions, for the Company, required it to deliver an undertaking confirming that, while listed on the Exchange, the Company will only conduct the business of production, acquisition, sale and distribution of medical marijuana in Canada as permitted under the Health Canada license. This undertaking could have an adverse effect on the Company's ability to export marijuana from Canada and on its ability to expand its business into other areas including the provision of non-medical marijuana in the event that the laws were to change to permit such sales and the Company is still listed on the Exchange and still subject to such undertaking at the time. This undertaking may prevent the Company from expanding into new areas of business when the OGI's competitors have no such restrictions. All such restrictions could materially and adversely affect the growth, business, financial condition and results of operations of the Company.

(xxv) Management of Growth

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. If OGI is unable to deal with this growth; that may have a material adverse effect on the Company's business, financial condition, results of operations and prospects.

(xxvi) Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which OHI becomes involved be determined against the Company, such a decision could adversely affect OHI's ability to continue operating and the market price for the Company's common shares and could use significant resources. Even if the Company is involved in litigation and wins, litigation can redirect significant company resources.

(xxvii) Dividends

The Company has no earnings or dividend record and may not pay any dividends on its common shares in the foreseeable future. Dividends paid by the Company could be subject to tax and, potentially, withholdings.

(xxviii) Limited Market for Securities

The Company's common shares are listed on the TSX-V, however, there can be no assurance that an active and liquid market for the common shares will be maintained and an investor may find it difficult to resell any securities of the Resulting Issuer.

(xxix) Environmental and Employee Health and Safety Regulations

OGI's operations are subject to environmental and safety laws and regulations concerning, among other things, emissions and discharges to water, air and land, the handling and disposal of hazardous and non-hazardous materials and wastes, and employee health and safety. OGI will incur ongoing costs and obligations related to compliance with environmental and employee health and safety matters. Failure to comply with environmental and safety laws and regulations may result in additional costs for corrective measures, penalties or in restrictions on our manufacturing operations. In addition, changes in environmental, employee health and safety or other laws, more vigorous enforcement thereof or other unanticipated events could require extensive changes to OGI's operations or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

7.2 Commitments and Contingent Liabilities

(i) Contingent Liabilities

The Company recognizes loss contingency provisions for probable losses when management is able to reasonably estimate the loss. When the estimated loss lies within a range, the Company records a loss contingency provision based on its best estimate of the probable loss. If no particular amount within that range is a better estimate than any other amount, the minimum amount is recorded. As information becomes known a loss contingency provision is recorded when a reasonable estimate can be made. The estimates are reviewed at each reporting date and the estimates are changed when expectations are revised. An outcome that deviates from the Company's estimate may result in an additional expense or release in a future accounting period.

During the prior year, the Company was named as a defendant in a law suit in New Brunswick for breach of confidence, conversion, breach of contract, conspiracy and breach of trust, breach of fiduciary duty, and negligent misrepresentation. The Company believes the law suit to be without merit though they will rigorously defend the action. A provision has been made in these consolidated financial statements for the claim.

On March 3, 2017, a Notice of Action was filed with the Supreme Court of Nova Scotia seeking certification to commence a class action lawsuit against the Company and OGI seeking damages in respect of any profits earned by the Company in respect of product which was sold to clients and subsequently voluntarily recalled.

The Company will be opposing certification and defending any action. While the legal analysis is ongoing, the Company does not believe, at this time, that there is a likelihood of damages being awarded to the class, in the event that the class is certified to proceed. The Company has recognized in the three-month period ended February 28, 2017, \$2,026,349 in sales returns for customer credits arising from the product recall which represents a divestiture of the profits earned through a client credit program.

8.1 Directors and Officers

The Company's directors and officers, as of the current date, are:

Greg Engel ¹	Director and CEO
Dr. Kenneth Mitton	Independent Director
Michel J. Bourque	Independent Director and Chair of the Compensation and Human Resources Committee, Governance and Nominating Committee
Monique Imbeault ¹	Independent Director
Denis Arsenault	Executive Chairman of the Board
Peter Amirault	Independent Director and Chair of the Audit Committee
Peter R. Hanson	Chief Financial Officer (interim)
Larry Rogers	Chief Operating Officer
Raymond Gracewood	Chief Commercial Officer
Michael Tripp ¹	Chief Legal Officer

Note: ¹Subject to Health Canada regulatory approval.